What special precautions should be taken when using entrectinib?

Entrectinib is a targeted drug mainly used to treat ALK and TRK (< span>NTRK) and ROS1 gene mutation-positive non-small cell lung cancer (NSCLC) and other tumors. As a tyrosine kinase inhibitor (TKI), it prevents the growth of tumor cells by inhibiting the mutated ALK, ROS1 and TRK pathways. Although entrectinib has shown significant clinical efficacy, some special precautions must be taken when using it.

1. Monitor liver function: The use of entrectinib may cause abnormal liver function, so during treatment, liver function needs to be monitored regularly, including liver enzymes (such as AST, ALT) and bilirubin levels. If liver function abnormalities are found, dose adjustment or treatment may need to be suspended. Patients with severely impaired liver function (such as those with hepatitis or cirrhosis) need to use entrectinib with special caution and adjust their treatment regimen based on clinical judgment. Regular liver function tests are recommended, especially during the initial stages of treatment.

2. Risk of QT prolongation: Entrectinib may cause prolongation of the QT interval on the electrocardiogram, especially when used at high doses. QTProlongation of the QT interval may lead to fatal cardiac arrhythmias (such as ventricular fibrillation), so regular ECG monitoring is required in patients taking this drug. If the QT interval is found to be significantly prolonged, your doctor may consider suspending or adjusting the drug dose. In addition, patients taking entrectinib should be particularly aware of this risk if they are also taking drugs that prolong the QT interval or have a history of heart disease.

3. Attention to drug interactions: Entrectinib is metabolized by the liver's CYP3A enzyme, so drug interactions may occur when used in combination with other drugs. Especially some drugs (such as powerfulCYP3Ainhibitors or inducers) may affect the pharmacokinetics of entrectinib. Patients should inform their doctors about all medications they are taking, including prescription, over-the-counter, and herbal medicines, while taking entrectinib to avoid potential drug interactions. Adjustment of the entrectinib dose or the selection of an alternative agent may be necessary.

4. Contraindicated use in pregnant and lactating women: Entrectinib may have adverse effects on the fetus during pregnancy, so entrectinib is contraindicated in pregnant women. If a patient becomes pregnant while taking entrectinib, she should stop taking entrectinib immediately and consult her doctor about treatment options. Entrectinib may also be excreted in breast milk, so breastfeeding women should also avoid using this drug. During treatment, female patients need to take effective contraceptive measures to prevent pregnancy and continue to take contraceptive measures for a period of time after treatment is completed. If the patient is breastfeeding, consideration should be given to discontinuing breastfeeding or discontinuing the drug.

Reference materials:https://www.roche.com/products/rozlytrek